Merck & Co Inc MRK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Merck Ends Development of Blood Cancer Drug Nemtabrutinib
Merck Raises Quarterly Dividend by 3.5%
Merck Gains Support for Broader Use of Preventive RSV Treatment
The science of vaccines is rapidly advancing - despite the anti-vax movement
Merck Says Investigational MASH Drug Shows Promise in Midstage Trial
Moderna Swings to 3Q Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes — Update
The big winners of the tech wreck are biopharma stocks
Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock closed at a record high.
Trading Information
- Previous Close Price
- —
- Day Range
- CHF 95.30–95.30
- 52-Week Range
- CHF 95.30–95.30
- Bid/Ask
- CHF 119.48 / CHF 121.22
- Shares Outstanding
- 2.47B
- Market Cap
- $235.37B
- Volume/Avg
- 50 / 50
Key Statistics
- Price/Earnings (Normalized)
- 114.43
- Price/Sales
- 5.66
- Dividend Yield (Trailing)
- 1.71%
- Dividend Yield (Forward)
- 2.44%
- Dividend Payment Schedule
- Apr, Jul, Oct
- Total Yield
- 2.64%
Company Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 75,000
- Website
- https://www.merck.com
Competitors
Valuation
Metric | MRK | LLY | PFE |
|---|---|---|---|
Price/Earnings (Normalized) | 114.43 | 44.31 | 13.10 |
Price/Book Value | 8.08 | 31.33 | 1.82 |
Price/Sales | 5.66 | 14.66 | 2.57 |
Price/Cash Flow | 17.22 | 34.99 | 11.04 |
Price/Earnings
MRK
LLY
PFE
Financial Strength
Metric | MRK | LLY | PFE |
|---|---|---|---|
Quick Ratio | 0.78 | 0.64 | 1.00 |
Current Ratio | 1.35 | 1.39 | 1.42 |
Interest Coverage | 3.33 | 33.96 | 2.39 |
Quick Ratio
MRK
LLY
PFE
Profitability
Metric | MRK | LLY | PFE |
|---|---|---|---|
Return on Assets (Normalized) | 2.53% | 22.55% | 8.49% |
Return on Equity (Normalized) | 7.02% | 91.88% | 19.73% |
Return on Invested Capital (Normalized) | 4.79% | 37.89% | 12.71% |
Return on Assets
MRK
LLY
PFE
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|FCWPW#> | LOCK|^pZ | $1T | |||
| Johnson & Johnson JNJ | LOCK|M^!bWf# | LOCK|G%x | $671B | |||
| AbbVie Inc ABBV | LOCK|!BLRXd% | LOCK|d@ | $518B | |||
| Roche Holding AG ADR RHHBY | LOCK|&fx>$S& | LOCK|x^^ | $386B | |||
| Merck & Co Inc MRK | LOCK|x#<&XK | LOCK|Q# | $353B | |||
| Novartis AG ADR NVS | LOCK|Cpc#@dbs | LOCK|dw | $300B | |||
| AstraZeneca PLC AZN | LOCK|QM&%%b@< | LOCK|yd | $282B | |||
| Amgen Inc AMGN | LOCK|BSn^@^Xl | LOCK|!?# | $248B | |||
| Gilead Sciences Inc GILD | LOCK|ZQFY>T# | LOCK|vpY | $211B | |||
| Novo Nordisk AS ADR NVO | LOCK|<dySG&b | LOCK|ql | $179B |